Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
$1.15
-9.4%
$1.57
$0.87
$3.08
$91.82M-0.311.37 million shs2.28 million shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$10.70
+7.3%
$5.49
$3.90
$15.00
$135.03M0.68290,243 shs1.44 million shs
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
$5.99
-0.8%
$6.17
$3.28
$9.82
$102.90M1.49114,755 shs37,708 shs
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
$0.54
-1.2%
$0.60
$0.43
$5.14
$21.28M0.31903,920 shs520,211 shs
5G Stocks: The Path Forward is Profitable Cover

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
0.00%-7.97%-17.53%-10.56%-49.00%
Lifevantage Corporation stock logo
LFVN
Lifevantage
0.00%+26.20%+86.70%+95.87%-20.37%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
0.00%+4.86%-24.41%+6.34%-1.24%
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
0.00%-13.67%-10.91%-11.56%-76.95%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
$1.15
-9.4%
$1.57
$0.87
$3.08
$91.82M-0.311.37 million shs2.28 million shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$10.70
+7.3%
$5.49
$3.90
$15.00
$135.03M0.68290,243 shs1.44 million shs
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
$5.99
-0.8%
$6.17
$3.28
$9.82
$102.90M1.49114,755 shs37,708 shs
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
$0.54
-1.2%
$0.60
$0.43
$5.14
$21.28M0.31903,920 shs520,211 shs
5G Stocks: The Path Forward is Profitable Cover

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
0.00%-7.97%-17.53%-10.56%-49.00%
Lifevantage Corporation stock logo
LFVN
Lifevantage
0.00%+26.20%+86.70%+95.87%-20.37%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
0.00%+4.86%-24.41%+6.34%-1.24%
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
0.00%-13.67%-10.91%-11.56%-76.95%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
2.75
Moderate Buy$8.50639.13% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
2.00
Hold$5.00-53.27% Downside
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
2.25
Hold$14.50142.07% Upside
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
1.80
Reduce$0.9576.84% Upside

Current Analyst Ratings Breakdown

Latest VTGN, BMEA, LFVN, and VRCA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/3/2026
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
Reiterated RatingSell (E+)
5/26/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
UpgradeHold (C-)Hold (C)
5/26/2026
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
Initiated CoverageBuy$12.00
5/11/2026
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
UpgradeStrong SellHold
5/7/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
DowngradeBuyHold$5.00
5/5/2026
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
Initiated CoverageBuyOutperform
5/5/2026
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
Initiated CoverageMarket Outperform$9.00
5/4/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
DowngradeHold (C)Hold (C-)
4/28/2026
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
Reiterated RatingBuy$12.00
4/20/2026
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
Reiterated RatingSell (E+)
4/8/2026
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
Reiterated RatingBuy$12.00
(Data available from 6/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
N/AN/AN/AN/A$0.42 per shareN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$228.53M0.59$1.18 per share9.07$2.75 per share3.89
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
$37.16M2.77N/AN/A$1.55 per share3.86
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
$789K26.98N/AN/A$2.44 per share0.22
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
-$61.80M-$0.68N/AN/AN/AN/A-265.37%-103.96%8/4/2026 (Estimated)
Lifevantage Corporation stock logo
LFVN
Lifevantage
$9.81M$0.4523.7816.46N/A2.94%23.89%12.47%N/A
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-$17.89M-$1.03N/AN/AN/A-47.97%-1,077.78%-40.76%8/11/2026 (Estimated)
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
-$51.42M-$1.89N/AN/AN/AN/A-109.72%-89.62%6/16/2026 (Estimated)

Latest VTGN, BMEA, LFVN, and VRCA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/1/2026Q4 2026
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
-$0.3377N/AN/AN/A$0.40 millionN/A
6/16/2026Q4 2026
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
-$0.3367N/AN/AN/A$0.40 millionN/A
5/12/2026Q1 2026
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-$0.59-$0.41+$0.18-$0.45$4.51 million$5.02 million
5/11/2026Q1 2026
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
-$0.24-$0.17+$0.07-$0.17N/AN/A
5/6/2026Q3 2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.12-$0.04$0.11$47.77 million$43.72 million
3/11/2026Q4 2025
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-$0.43-$0.51-$0.08-$0.57$4.52 million$5.09 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.201.87%N/A44.44%3 Years
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
N/AN/AN/AN/AN/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
N/AN/AN/AN/AN/A

Latest VTGN, BMEA, LFVN, and VRCA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/27/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.052.12%6/1/20266/1/20266/15/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
N/A
4.98
4.98
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.96
1.04
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
0.03
2.10
1.98
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
N/A
4.67
4.67

Institutional Ownership

CompanyInstitutional Ownership
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
96.72%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
42.45%
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
78.39%

Insider Ownership

CompanyInsider Ownership
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
10.60%
Lifevantage Corporation stock logo
LFVN
Lifevantage
21.95%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
54.00%
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
2.85%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
5072.30 million64.64 millionOptionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.62 million9.85 millionOptionable
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
4017.18 million7.90 millionNo Data
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
4039.62 million38.49 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biomea Fusion stock logo

Biomea Fusion NASDAQ:BMEA

$1.15 -0.12 (-9.45%)
Closing price 04:00 PM Eastern
Extended Trading
$1.16 +0.02 (+1.30%)
As of 06:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$10.70 +0.73 (+7.32%)
Closing price 04:00 PM Eastern
Extended Trading
$10.74 +0.04 (+0.41%)
As of 06:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Verrica Pharmaceuticals stock logo

Verrica Pharmaceuticals NASDAQ:VRCA

$5.99 -0.05 (-0.83%)
Closing price 04:00 PM Eastern
Extended Trading
$6.00 +0.00 (+0.08%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

VistaGen Therapeutics stock logo

VistaGen Therapeutics NASDAQ:VTGN

$0.54 -0.01 (-1.23%)
Closing price 04:00 PM Eastern
Extended Trading
$0.54 +0.00 (+0.15%)
As of 06:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.